TY - JOUR
T1 - MRD detection in multiple myeloma
T2 - Comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods
AU - Roshal, Mikhail
AU - Flores-Montero, Juan A.
AU - Gao, Qi
AU - Koeber, Maesa
AU - Wardrope, Jessica
AU - Durie, Brian G.M.
AU - Dogan, Ahmet
AU - Orfao, Alberto
AU - Landgren, Ola
N1 - Funding Information:
This work was supported by the International Myeloma Foundation and Memorial Sloan Kettering Core Grant P30 CA008748 from the National Institutes of Health, National Cancer Institute.
Publisher Copyright:
© 2017 by The American Society of Hematology.
PY - 2017/5/9
Y1 - 2017/5/9
N2 - In patients with multiple myeloma, obtaining posttreatment minimal residual disease (MRD) negativity is associated with longer progression-free survival and overall survival. Here, we compared the diagnostic performance of a single 10-color tube with that of a EuroFlow 8-color 2-tube panel for MRD testing. Bone marrow samples from 41 multiple myeloma patients were tested in parallel using the 2 approaches. Compared with the sum of the cells from the EuroFlow two 8-color tubes, the Memorial Sloan Kettering Cancer Center (MSKCC) single 10-color tube had a slight reduction in total cell number with a mean ratio of 0.85 (range, 0.57-1.46; P, .05), likely attributable to permeabilization of the cells. Percent of plasma cells showed a high degree of concordance (r2 5 0.97) as did normal plasma cells (r2 5 0.96), consistent with no selective plasma cell loss. Importantly, concordant measurement of residual disease burden was seen with abnormal plasma cells (r2 5 0.97). The overall concordance between the 2 tests was 98%. In 1 case, there was a discrepancy near the limit of detection of both tests in favor of the slightly greater theoretical sensitivity of the EuroFlow 8-color 2-tube panel (analytical sensitivity limit of MSKCC single 10-color tube: 6 cells in 1 million with at least 3 million cell acquisitions; EuroFlow 8-color 2-tube panel: 2 cells in 1 million with the recommended 10 million cell acquisitions).
AB - In patients with multiple myeloma, obtaining posttreatment minimal residual disease (MRD) negativity is associated with longer progression-free survival and overall survival. Here, we compared the diagnostic performance of a single 10-color tube with that of a EuroFlow 8-color 2-tube panel for MRD testing. Bone marrow samples from 41 multiple myeloma patients were tested in parallel using the 2 approaches. Compared with the sum of the cells from the EuroFlow two 8-color tubes, the Memorial Sloan Kettering Cancer Center (MSKCC) single 10-color tube had a slight reduction in total cell number with a mean ratio of 0.85 (range, 0.57-1.46; P, .05), likely attributable to permeabilization of the cells. Percent of plasma cells showed a high degree of concordance (r2 5 0.97) as did normal plasma cells (r2 5 0.96), consistent with no selective plasma cell loss. Importantly, concordant measurement of residual disease burden was seen with abnormal plasma cells (r2 5 0.97). The overall concordance between the 2 tests was 98%. In 1 case, there was a discrepancy near the limit of detection of both tests in favor of the slightly greater theoretical sensitivity of the EuroFlow 8-color 2-tube panel (analytical sensitivity limit of MSKCC single 10-color tube: 6 cells in 1 million with at least 3 million cell acquisitions; EuroFlow 8-color 2-tube panel: 2 cells in 1 million with the recommended 10 million cell acquisitions).
UR - http://www.scopus.com/inward/record.url?scp=85034210505&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85034210505&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2016003715
DO - 10.1182/bloodadvances.2016003715
M3 - Article
AN - SCOPUS:85034210505
VL - 1
SP - 728
EP - 732
JO - Blood advances
JF - Blood advances
SN - 2473-9529
IS - 12
ER -